Niyogi SK. Shigellosis. J Microbiol 2005;43(2):133-143.
WHO. Shigellosis: disease burden, epidemiology and case management. Wkly Epidemiol Rec 2005;80:93-100.
Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, et al. Broadly protective Shigella vaccine based on type III secretion apparatus protein. Infect Immun 2012;80(3):1222-1231.
Fontaine A, Arondel J, Sansonetti PJ. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1. Infect Immun 1988;56(12):3099-3109.
WHO Initiative for Vaccine Research (IVR). Diarrhoeal diseases. 2009. Available from: http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index.html.
Wong MR, Reddy V, Hanson H, Johnson KM, Tsoi B, Cokes C, et al. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb Drug Resist 2010;16(2):155-161.
Ye C, Lan R, Xia S, Zhang J, Sun Q, Zhang S, et al. Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneri. J Clin Microbiol 2010;48(2):419-426.
McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 2006;24(18):3735-3745.
Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, et al. Characterization of WRSs2 and WRSs3, new second-generation virG (icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 2010;28(6):1642-1654.
Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 2004;72(2):923-930.
Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1trial of CVD 1204 and CVD 1208. J Infect Dis 2004;190:1745-1754.
Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011;29(6):1347-1354.
Kotloff KL, Losonsky AG, Nataro JP, Wasserman SS, Hale TL, Taylor ND, et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995;13(5):495-502.
Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996;64(10):4074-4077.
Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001;69(3):1351-1357.
Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 2001;69(7):4545- 4553.
Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, et al. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Vaccine 2010;28(37):6076-6085.
Picking WL, Mertz JA, Marquart ME, Picking WD. Cloning, expression, and affinity purification of recombinant shigella flexneri invasion plasmid antigens IpaB and IpaC. Protein Expr Purif 1996;8(4):401-408.
Daniell H, Khan MS, Allison L. Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci 2002;7(2):84-91.
Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals 2008; 36(6):354-358.
Daniell H. Medical molecular farming: expression of antibodies, biopharmaceuticals and edible vaccines in plants. London: Kluwer Academic Publishers; 2003.
Sambrook J, Fritsch ER, Maniatis T. Molecular cloning, a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2003.
Sheerman S, Bevan MW. A rapid transformation method for Solanum tuberosum using binary Agrobactrum tumefaciens vectors. Plant Cell Rep 1987;7(1):13-16.
D'Aoust MA, Lavoie PO, Belles-Isles J, Bechtold N, Martel M, Vézina LP. Transient expression of antibodies in plants using syringe agroinfiltration. Methods Mol Biol 2009;483:41-50.
Jurado P, de Lorenzo V, Fernandez LA. Thioredoxin fusions increase folding of a single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin. J Mol Biol 2006;357(1):49-61.
Lammeli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5259):680-685.
MacRaea AF, Preiszner J, Ng S, Bolla RI. Expression of His-tagged Shigella IpaC in Arabidopsis. J Biotechnol 2004;112(3):247-253.
Maghari BM, Ardekani AM. Genetically modified foods and social concerns. Avicenna J Med Biotech 2011;3(3):109-117.
Ma JK, Drake WMP, Christou P, The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003;4(10):794-805.
Fischer R, Schillberg S. Molecular farming, plant made pharmaceuticals and technical proteins. Weinheim: Wiley-VCH Verlag GmbH & Co; 2004.
Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987;15(20):8125-8148.